TLSI Stock Gets Reduced EPS Forecast from HC Wainwright

Key Points

• HC Wainwright lowered TriSalus Life Sciences’ Q3 2026 EPS forecast to a loss of $0.14 per share from $0.12, while estimating losses of $0.04 for Q4 and $0.53 for full-year 2026. The firm maintained a “Buy” rating and $12 price target.
• Analyst sentiment remains mixed: three analysts rate TLSI a Buy, one a Hold and one a Sell, resulting in an overall “Hold” consensus and average price target of $10.20.
• TLSI opened at $4.61 after reportedly falling 7.8%; its latest quarterly results matched the $0.16-per-share loss estimate but exceeded revenue expectations, reporting $11.41 million versus the $10.27 million consensus.

TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Free Report) - Investment analysts at HC Wainwright dropped their Q3 2026 earnings estimates for TriSalus Life Sciences in a report released on Wednesday, September 23rd. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of ($0.14) for the quarter, down from their previous forecast of ($0.12). HC Wainwright currently has a "Buy" rating and a $12.00 price objective on the stock. The consensus estimate for TriSalus Life Sciences' current full-year earnings is ($0.31) per share. HC Wainwright also issued estimates for TriSalus Life Sciences' Q4 2026 earnings at ($0.04) EPS and FY2026 earnings at ($0.53) EPS.

TLSI has been the subject of several other research reports. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of TriSalus Life Sciences in a research report on Friday, August 7th. Wall Street Zen raised TriSalus Life Sciences from a "sell" rating to a "hold" rating in a research note on Sunday, August 23rd. Stifel Nicolaus set a $12.00 target price on TriSalus Life Sciences in a research note on Wednesday. Zacks Research upgraded TriSalus Life Sciences to a "hold" rating in a report on Thursday, September 10th. Finally, Guggenheim set a $12.00 price target on shares of TriSalus Life Sciences in a research report on Wednesday. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $10.20.

TriSalus Life Sciences Trading Down 7.8%

NASDAQ TLSI opened at $4.61 on Friday. The firm's 50 day moving average price is $4.90 and its two-hundred day moving average price is $4.32. The company has a debt-to-equity ratio of 5.05, a quick ratio of 4.97 and a current ratio of 5.35. TriSalus Life Sciences has a twelve month low of $2.20 and a twelve month high of $7.95. The stock has a market cap of $283.88 million, a price-to-earnings ratio of -3.55 and a beta of 0.44.

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.16) earnings per share for the quarter, hitting the consensus estimate of ($0.16). The firm had revenue of $11.41 million during the quarter, compared to analysts' expectations of $10.27 million.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Bank of America Corp DE lifted its stake in TriSalus Life Sciences by 1.9% in the first quarter. Bank of America Corp DE now owns 201,719 shares of the company's stock valued at $807,000 after acquiring an additional 3,703 shares during the last quarter. Cura Wealth Advisors LLC bought a new position in shares of TriSalus Life Sciences during the 2nd quarter valued at $36,000. Renaissance Technologies LLC bought a new position in shares of TriSalus Life Sciences during the 1st quarter valued at $124,000. Deutsche Bank AG acquired a new stake in shares of TriSalus Life Sciences in the 2nd quarter valued at $221,000. Finally, Corient Private Wealth LP lifted its stake in shares of TriSalus Life Sciences by 61.7% in the 2nd quarter. Corient Private Wealth LP now owns 147,152 shares of the company's stock valued at $670,000 after purchasing an additional 56,152 shares during the last quarter. 2.58% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting TriSalus Life Sciences

Here are the key news stories impacting TriSalus Life Sciences this week:

• Positive Sentiment: FDA clearance for TriNav Advance, a device intended for liver embolization procedures, strengthens TriSalus’s product portfolio and could support future adoption, revenue growth and commercial momentum. The shares rose substantially following the announcement. TriSalus Life Sciences Shares Rise After Receiving FDA Clearance for TriNav Advance
• Positive Sentiment: HC Wainwright raised its price target for TLSI to $12 from $11 and maintained a “Buy” rating. The new target implies substantial upside from the reference price and reinforces the bullish case among some analysts.
• Positive Sentiment: The FDA decision generated notable investor interest and elevated trading activity, suggesting that the regulatory milestone is currently the main explanation for the stock’s upward move. Update: TriSalus Life Sciences Shares Rise After Receiving FDA Clearance for TriNav Advance

About TriSalus Life Sciences

TriSalus Life Sciences is an oncology company focused on developing technologies and therapies for patients with liver and pancreatic tumors. The company's approach combines investigational immunotherapies with drug-delivery technologies intended to improve treatment access to solid tumors, which can be difficult to reach through conventional systemic administration.

TriSalus is best known for its Pressure-Enabled Drug Delivery (PEDD) platform, which is designed to deliver medicines directly into tumors or their surrounding blood vessels by using controlled pressure.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.